Mankind Pharma Stock Screener | Share Price & Fundamental Analysis
MANKIND
Pharmaceuticals
Screen Mankind Pharma share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹2195.00
▼
-7.70 (-0.35%)
Share Price BSE
₹2193.45
▼
-9.10 (-0.41%)
Market Cap
₹89,624.11 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
5.93
EPS (TTM)
₹49.28
Dividend Yield
-
Debt to Equity
0.37
52W High
₹2919.70
52W Low
₹2106.00
Operating Margin
22.00%
Profit Margin
12.75%
Revenue (TTM)
₹3,333.00
EBITDA
₹933.00
Net Income
₹425.00
Total Assets
₹27,760.00
Total Equity
₹14,568.00
Mankind Pharma Share Price History - Stock Screener Chart
Screen MANKIND historical share price movements with interactive charts. Analyze price trends and patterns.
Mankind Pharma Company Profile - Fundamental Screener
Screen Mankind Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for MANKIND shares.
Mankind Pharma Limited is an Indian pharmaceutical company incorporated in 1991. It develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. The company operates in various therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. Mankind Pharma entered the consumer healthcare segment in 2007 and has since expanded into animal healthcare, female infertility treatments, and oncology. The company operates 23 manufacturing facilities across India with a total installed capacity of 40.77 billion units as of March 31, 2022. In April 2023, Mankind Pharma went public through an Initial Public Offer. The company has acquired several subsidiaries and brands, and has expanded internationally with subsidiaries in the US, Singapore, Nepal, and UAE.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
RAMESH CHAND JUNEJA
ISIN
INE634S01028
Website
https://www.mankindpharma.com
Mankind Pharma Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen MANKIND balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Total Assets | 27,760 | 11,963 | 9,715 | 9,148 | 6,373 |
| Current Assets | 6,988 | 6,568 | 4,328 | 4,407 | 3,907 |
| Fixed Assets | 19,005 | 4,545 | 4,251 | 3,588 | 1,664 |
| Liabilities | |||||
| Total Liabilities | 27,760 | 11,963 | 9,715 | 9,148 | 6,373 |
| Current Liabilities | 7,528 | 268 | 229 | 208 | 156 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||
| Total Equity | 14,568 | 9,576 | 7,623 | 6,316 | 4,863 |
| Share Capital | 41 | 40 | 40 | 40 | 40 |
| Reserves & Surplus | 14,291 | 9,323 | 7,395 | 6,115 | 4,682 |
Screen MANKIND income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,333 | 3,653 | 3,791 | 2,517 | 2,976 | 3,173 | 3,286 | 2,103 | 2,642 | 2,772 | 2,682 | 1,764 | 2,200 | 2,457 | 2,130 |
| Expenses | 2,401 | 2,724 | 2,776 | 1,836 | 2,196 | 2,217 | 2,383 | 1,636 | 1,924 | 2,025 | 2,000 | 1,441 | 1,724 | 1,835 | 1,654 |
| EBITDA | 933 | 930 | 1,016 | 681 | 780 | 956 | 903 | 467 | 718 | 746 | 681 | 323 | 476 | 622 | 477 |
| Operating Profit % | 22.00% | 24.00% | 25.00% | 24.00% | 23.00% | 28.00% | 26.00% | 20.00% | 25.00% | 25.00% | 23.00% | 17.00% | 21.00% | 24.00% | 21.00% |
| Depreciation | 231 | 219 | 222 | 100 | 103 | 101 | 187 | 85 | 87 | 97 | 110 | 47 | 78 | 79 | 85 |
| Interest | 191 | 171 | 170 | 9 | 11 | 7 | 221 | 5 | 6 | 9 | 9 | 13 | 16 | 10 | 13 |
| Profit Before Tax | 511 | 541 | 624 | 572 | 666 | 849 | 495 | 377 | 625 | 641 | 562 | 263 | 382 | 533 | 379 |
| Tax | 86 | 96 | 104 | 95 | 123 | 190 | 111 | 84 | 130 | 130 | 103 | 70 | 84 | 110 | 83 |
| Net Profit | 425 | 445 | 520 | 477 | 543 | 659 | 385 | 294 | 494 | 511 | 460 | 193 | 298 | 423 | 296 |
| EPS | 10.19 | 10.62 | 12.39 | 11.76 | 13.39 | 16.31 | 9.46 | 7.13 | 12.15 | 12.51 | 11.33 | 4.74 | 7.30 | 10.48 | 7.09 |
Mankind Pharma Cash Flow Screener - Liquidity Fundamentals
Screen MANKIND cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March |
|---|---|---|---|---|---|---|
| Operating Activities | 2,413 | 2,152 | 1,813 | 920 | 1,137 | 1,070 |
| Investing Activities | -12,624 | -2,081 | -1,052 | -1,369 | -1,222 | -436 |
| Financing Activities | 10,233 | 5 | -740 | 605 | -8 | -531 |
| Net Cash Flow | 22 | 77 | 22 | 156 | -92 | 103 |
Screen MANKIND shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 72.70% | 72.68% | 72.67% | 74.88% | 74.87% | 74.87% | 72.71% | 76.50% |
| FII Holding | 12.92% | 13.07% | 12.84% | 9.87% | 11.58% | 12.37% | 13.34% | 0.00% |
| DII Holding | 11.48% | 11.50% | 11.92% | 11.14% | 9.95% | 9.90% | 11.06% | 2.64% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 1.64% | 1.52% | 1.36% | 1.22% | 1.46% | 1.55% | 1.60% | 4.15% |
| Other Holding | 1.26% | 1.23% | 1.21% | 2.89% | 2.15% | 1.31% | 1.30% | 16.71% |
| Shareholder Count | 180,597 | 179,549 | 170,347 | 135,116 | 153,450 | 163,854 | 172,431 | 402,322 |
Mankind Pharma Dividend Screener - Share Yield Analysis
Screen MANKIND dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Mankind Pharma Index Membership - Market Screener Classification
Screen MANKIND by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Mankind Pharma Market Events Screener - Corporate Actions
Screen MANKIND market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | -2.56% |
| 2025-08-08 | 2025-08-08 | Dividend | ₹ 1.00 /share | -1.29% |
| 2025-08-07 | 2025-08-07 | Annual General Meeting | NA | 6.99% |
| 2025-07-31 | 2025-07-31 | Quarterly Result Announcement | NA | -0.12% |
| 2025-05-21 | 2025-05-21 | Quarterly Result Announcement | NA | 4.96% |
| 2025-01-23 | 2025-01-23 | Quarterly Result Announcement | NA | -8.15% |
| 2024-11-05 | 2024-11-05 | Quarterly Result Announcement | NA | 9.09% |
| 2024-08-09 | 2024-08-09 | Annual General Meeting | NA | -2.17% |
Mankind Pharma Competitors Screener - Peer Comparison
Screen MANKIND competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,518 | 39.35 | 54,729 | 9.71% | 10,980 | 38.94 |
| Divis Laboratories | 167,989 | 68.31 | 9,712 | 18.67% | 2,191 | 47.61 |
| Torrent Pharmaceuticals | 129,963 | 60.76 | 11,539 | 6.99% | 1,911 | 63.27 |
| Cipla | 121,133 | 22.46 | 28,410 | 7.12% | 5,291 | 50.85 |
| Dr Reddys Laboratories | 104,304 | 18.49 | 33,741 | 16.73% | 5,725 | 53.02 |
| Lupin | 96,133 | 22.19 | 22,910 | 13.74% | 3,306 | 57.47 |
| Zydus Life Science | 92,020 | 18.30 | 23,511 | 18.55% | 4,615 | 43.59 |
| Mankind Pharma | 89,624 | 51.11 | 12,744 | 20.90% | 2,007 | 49.10 |
| Aurobindo Pharma | 69,121 | 20.05 | 32,346 | 9.43% | 3,484 | 45.26 |
| Alkem Laboratories | 65,390 | 27.31 | 13,458 | 3.70% | 2,216 | 41.76 |
Mankind Pharma Company Announcements - News Screener
Screen MANKIND latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-12-29 | Closure of Trading Window | View |
| 2025-12-29 | Closure of Trading Window | View |
| 2025-12-10 | Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations) | View |
| 2025-12-10 | Intimation Regarding ESG Rating | View |
| 2025-11-28 | Intimation Regarding ESG Rating | View |
| 2025-11-26 | Announcement under Regulation 30 (LODR)-Allotment | View |
| 2025-11-16 | Intimation Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 | View |
| 2025-11-15 | Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Credit Rating | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-11 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-06 | Financial Results For The Quarter And Half Year Ended 30Th September 2025 | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-06 | Board Meeting Outcome for Outcome Of Board Meeting | View |
| 2025-11-04 | Intimation Regarding ESG Rating | View |
| 2025-10-29 | Intimation Regarding ESG Rating | View |